Full Text View
Tabular View
No Study Results Posted
Related Studies
A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence
This study is currently recruiting participants.
Verified May 2013 by Massachusetts General Hospital
Study NCT01480232   Information provided by Massachusetts General Hospital

First Received on November 23, 2011.   Last Updated on May 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Nicotine Dependence
Smoking Cessation
Additional conditions recognized in this trial
Smoking
Tobacco Use Disorder
More general conditions related to this trial
Habits
Mental Disorders
Substance-Related Disorders
Interventions listed in this trial
EVP-6124
Placebo Capsule
NicoDerm CQ Patch (Active)
NRT Patch (Placebo)
Additional drug interventions recognized in this trial
Nicotine
Nicotine polacrilex
Nicotinic Agonists
More general drug interventions related to this trial
Autonomic Agents
Central Nervous System Agents
Central Nervous System Stimulants
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
A. Eden Evins
EnVivo Pharmaceuticals, Inc.
National Institute on Drug Abuse (NIDA)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services